Please provide your email address to receive an email when new articles are posted on . GlaxoSmithKline and Innoviva’s triple-combination therapy of fluticasone furoate, umeclidinium and vilanterol ...
London, UK, Thursday 23 March 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress ...
GlaxoSmithKline plcGSK, with its partner Innoviva, Inc. INVA, announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy (fluticasone furoate, ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Symbicort Turbuhaler contains two active ingredients in one inhaler: ...
GlaxoSmithKline has filed with the European Medicines Agency its Innoviva-partnered, once-daily, closed triple combination therapy as a treatment for patients with chronic obstructive pulmonary ...
3.1 ICSs suppress inflammation in the lungs and are recommended for prophylactic treatment of asthma. In the UK, three ICSs are licensed for use in children: beclometasone dipropionate, budesonide and ...
LONDON, Oct 18 (Reuters) - AstraZeneca Plc lost a key European patent on its two-in-one asthma drug Symbicort on Thursday but the drugmaker said it did not expect the move to have an immediate impact ...
GlaxoSmithKline plc and Innoviva, Inc. announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results